PAM 50 in breast cancer
Reading Document
Medical Text Search
PAM50 breast cancer intrinsic subtypes molecular classification
Medical Text Search
PAM50 ROR score prognosis treatment breast cancer clinical use
GradeResponse
GradeResponse
Here is a comprehensive overview of PAM50 in breast cancer:
PAM50 (Prosigna) in Breast Cancer
What Is PAM50?
PAM50 is a 50-gene expression signature used to classify breast cancer into intrinsic molecular subtypes and generate a quantitative risk score. The commercial assay based on PAM50 is called Prosigna, which uses NanoString nCounter technology on formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
The Four Intrinsic Subtypes
PAM50 classifies tumors into one of four molecular subtypes, each with distinct biology, prognosis, and therapeutic implications:
| Subtype | Key Features | Prognosis |
|---|---|---|
| Luminal A | ER+, low proliferation, low-grade | Best; low recurrence risk |
| Luminal B | ER+, higher proliferation, may be HER2+ | Intermediate; higher recurrence risk than Luminal A |
| HER2-enriched | HER2 overexpression (may be ER−) | Intermediate-poor without anti-HER2 therapy |
| Basal-like | ER−/PR−/HER2− (triple-negative overlap) | Worst overall; chemo-sensitive |
A fifth category — Normal-like — is sometimes reported but has uncertain clinical significance.
The Risk of Recurrence (ROR) Score
PAM50's primary clinical output is the Risk of Recurrence (ROR) score, a continuous 0–100 score integrating:
- The molecular subtype assignment
- Proliferation score (derived from the 50 genes)
- Tumor size (in the Prosigna version)
ROR is stratified into:
- Low risk: ROR < 40 (approximately; thresholds vary by nodal status)
- Intermediate risk: ROR 40–60
- High risk: ROR > 60
According to Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer (p. 11), the ROR score is most validated through retrospective analyses of prospective randomized trials and population-based studies — distinguishing it from Oncotype DX, which has a prospective trial (TAILORx). There are currently no prospective randomized clinical utility trials specific to Prosigna/PAM50.
Clinical Indications
PAM50/Prosigna is primarily used in HR+, HER2−, early-stage breast cancer to guide adjuvant chemotherapy decisions:
- Node-negative disease: Identifies patients at low risk who can safely forgo chemotherapy
- Node-positive (1–3 nodes): Can stratify patients at high vs. low risk of late recurrence (years 5–10), helping guide extended endocrine therapy decisions (e.g., adding abemaciclib or continuing aromatase inhibitor)
Key validated datasets include:
- ABCSG-8 and ATAC trials: validated ROR for predicting distant recurrence in postmenopausal ER+/HER2− patients
- TransATAC and AZURE studies: further validation of late recurrence prediction
PAM50 vs. Other Genomic Tests
| Feature | PAM50 (Prosigna) | Oncotype DX (RS) | Mammaprint |
|---|---|---|---|
| Genes | 50 | 21 | 70 |
| Technology | NanoString | RT-PCR | Microarray |
| Output | Subtype + ROR score | Recurrence Score (0–100) | Binary (High/Low) |
| Prospective trial | No | Yes (TAILORx, RxPONDER) | Yes (MINDACT) |
| Node-positive data | Yes (1–3 nodes) | Yes (RxPONDER) | Yes (MINDACT) |
| Late recurrence prediction | Strong | Moderate | Moderate |
PAM50 is particularly notable for its late recurrence prediction (beyond 5 years), which is clinically relevant when deciding on extended adjuvant endocrine therapy.
Guideline Recommendations
- ASCO 2022 / NCCN: Prosigna is listed as an option for multigene assay testing in HR+/HER2−/node-negative and select node-positive patients, particularly postmenopausal women
- The St. Gallen Consensus and ESMO guidelines recognize PAM50 as a validated genomic tool, especially for identifying Luminal A vs. Luminal B biology beyond standard IHC surrogates
- Preferred in some European health systems (UK NHS, some Nordic countries) where it has regulatory approval and health-technology assessment support
Key Clinical Pearl: IHC vs. PAM50 Subtyping
Clinical IHC-based subtyping (using ER, PR, HER2, Ki-67) is a surrogate for intrinsic subtyping. PAM50 reclassifies a meaningful proportion of patients:
- ~20–30% of IHC "Luminal B" tumors are reclassified as Luminal A by PAM50
- Some IHC Luminal A tumors are upstaged to Luminal B
- This reclassification has direct implications for chemotherapy recommendation and prognosis counseling
Summary
PAM50/Prosigna serves two main functions in clinical breast oncology:
- Molecular subtype classification — providing biologic insight beyond IHC
- ROR score — quantifying 10-year distant recurrence risk to personalize adjuvant therapy decisions
Its strongest niche is late recurrence prediction in postmenopausal HR+ early breast cancer, though the absence of a prospective utility trial remains a limitation compared to Oncotype DX.
This is a shared conversation. Sign in to Orris to start your own chat.